Status:
COMPLETED
Effect of Metoprolol on Thalassemia Cardiomyopathy
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
B Thalassemia
Eligibility:
All Genders
13-25 years
Phase:
PHASE2
PHASE3
Brief Summary
effect of B blocker was first evaluated in patient with cardiomyopathy not induced by ischemia and idiopathic which as the most common causes of cardiomyopathy. Effect of BB on Thalassemia cardiomyopa...
Detailed Description
In this clinical trial, 45 patients with thalassemia cardiomyopathy were randomized to receive either metoprolol (n = 26) or placebo (n = 19). Echocardiography and 6 minute walk test was performed at ...
Eligibility Criteria
Inclusion
- documented LVEF \< 50% by echocardiography
- B thalassemia
- No decompensated heart failure for at least 4 weeks (hospitalization for CHF, worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)
- have no evidence of acute myocarditis and
- hemoglobin level above 7 gr⁄dL.
Exclusion
- pulse rate below 60/min
- systolic blood pressure less than 90 mmHg
- evidence of peripheral vascular disease
- major depression, history of asthma, PR interval more than 240 msec, second or third degree AV block
- major medical diseases including diabetes mellitus requiring insulin injection, hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for human immunodeficiency virus, and other hemoglobinopathies
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01863173
Start Date
January 1 2012
End Date
December 1 2012
Last Update
May 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shiraz University of Medical Sciences
Shiraz, Fars, Iran